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The gut microbiota refers to the trillions of microorganisms residing in the intestine and is integral in multiple physiological
processes of the host. Recent research has shown that gut bacteria play a role in metabolic disorders such as obesity, diabetes, and
cardiovascular diseases. The mechanisms by which the gut microbiota aﬀects metabolic diseases are by two major routes: (1) the
innate immune response to the structural components of bacteria (e.g., lipopolysaccharide) resulting in inﬂammation and (2)
bacterial metabolites of dietary compounds (e.g., SCFA from ﬁber), which have biological activities that regulate host functions.
Gut microbiota has evolved with humans as a mutualistic partner, but dysbiosis in a form of altered gut metagenome and collected
microbial activities, in combination with classic genetic and environmental factors, may promote the development of metabolic
disorders. This paper reviews the available literature about the gut microbiota and aforementioned metabolic disorders and reveals
the gaps in knowledge for future study.
1.Introduction
Obesity results from the accumulation of excess adipose
tissue;however,itisnotasingledisorderbutaheterogeneous
group of conditions with multiple causes. Major causes of
the increasing prevalence of obesity include behavioral and
environmental factors, such as excessive consumption of
energy-dense foods and a sedentary lifestyle [1]. Still, it is
now recognized that a series of underexplored physiological
and environmental predispositions underlies the traditional
riskfactorsforobesityanditsassociatedmetabolicdisorders.
In this regards, gut microbiota has recently been proposed
as an environmental factor responsible for the weight gain
and the altered energy metabolism that accompanies the
obese state. Gut microbiota aﬀects host metabolism by
increased energy extraction, immune system modulation,
andalteredlipidmetabolism.Furthermore,boththephysical
presence of bacteria and the metabolites from bacteria are
responsible for these eﬀects. An evaluation of the evidence
indicating that the gut microbiota plays a role in energy
balance and obesity-associated diseases such as diabetes
and cardiovascular diseases (CVDs), as well as factors that
mediate these hard endpoints, is presented in this paper.
2. Composition of the Microbiota in the Human
GastrointestinalTract
Microbiota is a collection of microorganisms including
bacteria, archaea, viruses, and some unicellular eukaryotes.
Microbiota is associated with every multicellular organism
on earth. In humans, it has been estimated that 1014
microorganisms reside in various parts of the body such as
the surface of skin and in the gastrointestinal, genitourinary,
and respiratory tracts. The gastrointestinal tract, which
has the largest number of microorganisms in humans, is
comprised of specialized compartments such as the mouth,
esophagus, stomach, small intestine, large intestine (colon),
rectum, and anus. Each of these compartments has unique
physiological functions and anatomical structures. As a
result, the chemical environment and habitable microorgan-
isms diﬀer tremendously in each compartment (Figure 1). In
the colon, up to 1012 microorganisms/mL are reported. This
is by far the highest density found in humans [2–4], and
the vast majority of microorganisms belong to the phyla of
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacte-
ria, with relatively lower numbers belonging to Fusobacteria,
Verrucomicrobia, and TM7 [4–8]. Fungi and Archaea may2 Journal of Obesity
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Figure 1: Association of the microbiota with humans. Microbiota presents in all parts of our body which has direct contact with external
environment. The numbers of bacteria in the mouth (1010), on the skin (1012), and in the distal gut (1014) are presented in a relation to
total number of parenchymal cells (1012). The composition of the microbiota in the digestive tract greatly diﬀe r si ne a c ho fs p e c i a l i z e d
compartments as illustrated [6, 13–15]. Physiological functions and chemical environment of each compartment are likely key factors
inﬂuencing the bacterial habitants.
also be resident [6, 9, 10], but comprise less than 1% of
the total inhabitants. Altogether, a human gastrointestinal
microbiota comprises more than 10,000 diﬀerent phylotype
s, most of which have not been characterized by a culturing
technique or even sampled to date [8, 11]. However, this
notion has been challenged by a recent ﬁnding by Goodman
et al. who reported that 99% of the bacteria characterized in
the phylum, class, and order level could also be found in the
biomass from an anaerobic culture of original fecal samples
[12].
3.GutMicrobiotaandObesity
3.1. The Gut Microbiota Proﬁle in Obesity. Several studies
reportedbymembersoftheGordon’slabshowedthatthegut
microbiota diﬀers at the phylum level depending on weight
status [7, 16, 17]. In agreement with results from animal
studies,itappearsthathumanobesityisassociatedwithalow
abundance of intestinal Bacteroidetes and high abundance
of Firmicutes. However, this result has been contradicted by
other studies. Duncan et al. showed that no diﬀerence was
found in the proportions of Bacteroidetes and Firmicutes in
the feces of lean and obese subjects [18]. In another study,
overweight and obese subjects had a ratio of Bacteroidetes to
Firmicutes in favor of Bacteroidetes [19]. Recently, Jumpertz
et al. applied the state-of-the-art pyrosequencing technique
to examine the bacterial 16S rRNA genes and reported that
no phylum level diﬀerence was found in between the obese
and lean fecal microbiota [20]. Therefore, the phylum level
diﬀerence of the gut microbiota between obese and lean
individuals might not be universally true.
Compositional changes of the human gut microbiota in
response to weight change have been examined by many
groups. Ley et al. monitored the fecal gut microbiota in
12 obese subjects participating in a weight-loss program by
consuming restricted diets for a year [7]. Following weight
loss, the proportion of Bacteroidetes increased while the
number of Firmicutes reciprocally decreased. Fecal micro-
biota compositions of overweight and obese adolescents
also were determined in the EVASYON study group. After
10 weeks of energy restriction and exercise, participants
who lost more than 4kg body weight showed a signiﬁcant
increase in the population of Bacteroides fragilis group, as
determined by a quantitative PCR technique [21]. Another
EVASYON cohort study also reported that an increase in
Bacteroides/Prevotella group positively correlated with the
amount of weight loss [22].Journal of Obesity 3
To date, the most eﬀective treatment for morbid obesity
is gastric bypass surgery. The consequences of gastric bypass
surgery in the composition of the fecal microbiota have been
studied. Zhang et al. found that obesity was associated with
an increase of family Prevotellaceae prior to the surgery, and
following surgery Prevotellaceae was reduced to the level
of lean individuals whereas other bacteria such as family
Enterobacteriaceae and genus Akkermansia were enhanced
[23]. In another clinical study, the number of fecal E. coli
species was increased at 3 and 6 months after having gastric
bypass surgery [24]. The impact of gastric bypass surgery
on the gut microbiota proﬁle in animals was an increase
in the proportion of Enterobacter hormaechei by 200- and
42.8-fold at 2 and 8 weeks after the surgery, respectively
[25]. Since both E. coli species and E. hormaechei belong
to the family Enterobacteriaceae, a proportional increase of
Enterobacteriaceae could be a common outcome of gastric
bypass surgery. However, it is not known whether changes
in Enterobacteriaceae populations are linked to the rapid
weight loss and improvement of insulin sensitivity resulting
from gastric bypass surgery.
3.2. Gut Microbiota as a Modulator of Obesity:
Host Genome and Dietary Fats
3.2.1.HostGenome. Animalstudieshaveshownthatthehost
genome modulates gut microbiota composition. Obesity
caused by a leptin mutation in mice (ob/ob) is associated
with altered gut microbiota proﬁles [16, 17]. Ley et al. [16]
analyzed more than 5000 bacterial 16S rRNA gene sequences
from the cecal content of ob/ob mice, their lean ob/+ and
+/+ siblings, and their ob/+ mothers. Homozygous ob/ob
mutation coincided with 50% fewer Bacteroidetes and a
proportional increase in Firmicutes in the gut. The gut
microbiota proﬁle of mice with a leptin receptor mutation
(db/db) has recently been published [26]. In accordance to
ob/ob mice, db/db mice cecal microbiota was characterized
with higher abundance of phylum Firmicutes and lower
abundance of phylum Bacteroidetes compared to the lean
mice. Furthermore, certain genera such as Odoribacter, Pre-
votella, and Rikenella only present in the ceca of db/db mice,
whereas Enterorhabdus presents in the ceca of lean mice.
However, it is possible that the alterations in the bacterial
composition in ob/ob and db/db mice are secondary to
hyperphagia. A careful pair-feeding experiment would be
needed to show if the amount of food intake contributes
to the signature of gut microbiota associated with genetic
obesity in mice.
3.2.2. Dietary Fats. While the host genotype has been proven
to aﬀect microbiota, the eﬀect of diet, speciﬁcally dietary
fat, also plays an important role in determining bacterial
composition. A high-fat-fed animal displays a signiﬁcant
shiftinbothbacterialandmetagenomicproﬁlesascompared
toananimal on anormal, chow diet. Western diet-associated
cecal microbiota is characterized with a reduction in the
relative abundance of Bacteroidetes and an increase in the
relative abundance of Firmicutes. In particular Mollicutes,
a class of Firmicutes, has been found to be signiﬁcantly more
prevalent in CONV mice fed a Western-type diet [27]. An
increase of genes involved in the import and processing of
sugars in the gut metagenome was also found in Western
diet-fed mice [27]. Examination of the role of the Western
diet-associated cecal microbiota in facilitating weight gain
has revealed that ex-GF mice receiving the Western diet-
associated gut microbiota gained signiﬁcantly more body
fat than the mice receiving the chow diet-associated gut
microbiota [27]. Murphy et al. reported that C57BL/6J mice
responded to HF feeding with a progressive increase in
abundance of Firmicutes over time [28]. Ravussin et al.
also reported that in weight-matched animals, high-fat
feeding was associated with an increase in the family of
Lachnospiraceae and genera Bacteroides and Mucispirillum
whereas low fat feeding was associated with an increase in
genus Allobaculum [29].
The literature evidence further suggests that quality
of the diet instead of the weight of animals is stronger
modulator to the composition of the gut microbiota. It was
found that diet explained 57% of the bacterial variation in
the gut while genetic background only accounted for 12% of
the variation in animals [30], which suggests the primacy of
diet in determining the composition of the gut microbiota.
Hildebrandt et al. reported a similar ﬁnding in that mice
deﬁcient in RELMβ gene had moderate impacts on the gut
microbiota proﬁle whereas high-fat feeding caused greater
changes in the composition of the gut microbiota [31].
Metagenomic analysis of normal weight (RELMβ deﬁcient)
and obese mice (wildtype ) fed a high-fat diet found that the
diet, rather than weight or genetic status, correlated with an
increase in nutrient-transport genes and a decrease in amino
acid and carbohydrate metabolism genes [31]. These data
support the inﬂuence of the diet composition in the diversity
and proﬁles of the gut microbiota in mice; however, the
mechanism by which high-fat diets change the microbiota’s
functionality requires further study. Within the context of
obesity, it appears that genetics may determine initial gut
composition, but dietary fat is a potent modulator.
3.3. Mechanisms Linking the Gut Microbiota to Obesity
3.3.1. Inﬂammation. The interaction between the gut envi-
ronmentanddiet(modulatedbybacterialcomposition)may
explain why genetically identical mice respond diﬀerently
to a high-fat diet—some are prone and some resistant to
weight gain. Sprague-Dawley male rats prone to weight gain
exhibited ileal inﬂammation, decreased intestinal alkaline
phosphatase activity (enzyme which detoxiﬁes the bacterial
component known to cause inﬂammation, lipopolysac-
charide, or LPS), and increased innate immune system
activation in the luminal wall as compared to the obesity-
resistant rats [32]. Both obesity-prone and obesity-resistant
rats had an overall decrease in bacteria on the high-fat diet;
however,Enterobacteriales increasedintheobesity-pronerats
on a high-fat diet. In a study of genetically identical male
rats, infusing a low level of LPS for 4 weeks caused the same
amount of weight gain as a high-fat diet [33]. Rats that had4 Journal of Obesity
aknockoutofanimmunoprotein(CD14),whichisnecessary
to cause an inﬂammatory reaction to LPS, were immune to
weight gain [33]. Together the data show that rats naturally
prone to weight gain on a high-fat diet have intestinal
inﬂammation, inﬂammation alone can cause weight gain
in normal rats, and the absence of inﬂammation protects
rats against weight gain from a high-fat diet. Therefore, it is
hypothesized that the inﬂammatory mileu is integral in the
development of obesity.
3.3.2. Fiaf. The mere presence of gut microbiota has recently
been shown to contribute to obesity. A series of experiments
comparing the germ-free (GF) to conventional (CV) mice
concluded that the development of diet-induced obesity
requires the colonization of complex gut microbiota [34–
36].Microbiotatransplantationexperimentsshowedthatthe
accumulation of body fat depends on the type of the gut
microbiota, which supports the role of the gut microbiota
in the development of obesity [17, 27]. Mechanistically, the
acceleration of fat mass gain in conventionalized mice can
be partly explained by the suppression of hepatic de novo
lipogenesisandbytheinhibitionoftriglyceridestorageinthe
white adipose tissue. The latter eﬀect is thought to be caused
byanexcessiveproductionofFiaf(fasting-inducedadipocyte
factor or ANGPTL4) in the intestine of the GF mice [34].
Fiaf inhibits lipoprotein lipase (LPL) thereby blocking the
disassociationoffattyacidsfromtriglyceridesforuptakeinto
tissues and upregulating fatty acid oxidation and uncoupling
proteins,potentiallyreducingtheamountoffatstorageinGF
mice [37]. Fiaf also plays a role in the metabolic adaption to
fasting via PPAR activation [38]. The importance of Fiaf as a
mediator by which the gut microbiota regulates body weight
was demonstrated in GF Fiaf-knockout mice. Unlike the GF
wild-typeanimals,GFmicelacking Fiafresponded toahigh-
fat diet with excessive weight gains [39].
Although the function of Fiaf in blocking LPL activity is
clear, the extent to which Fiaf from the intestine as compared
toadiposetissueiscausingthiseﬀecthasnotbeenelucidated.
Initial studies characterizing Fiaf showed that it is located
primarily in white and brown adipose tissue, as well as
in the liver during fasting, and has a very low expression
in small intestine [38]. Moreover, Fleissner et al. found an
increase in intestinal Fiaf mRNA in GF mice but no increase
in secreted plasma protein levels compared to CONV mice
[40]. In a global Fiaf-knockout model, all Fiaf including
that in the adipose tissue and in the intestine is eliminated,
which diminishes the ability to determine the tissue speciﬁc
contribution of Fiaf to the phenotype. Therefore, available
evidence does not indicate that intestine-derived Fiaf has
a signiﬁcant impact on regulating the triglyceride storage
in the adipose tissue, and perhaps the lack of weight gain
in GF mice is due to other mechanisms. Determining the
physiological contribution of intestinal Fiaf as well as its
regulation by speciﬁc bacterial populations and metabolites
warrants further investigation.
3.3.3. Energy Harvesting. Another mechanism by which the
gut microbiota aﬀects body weight is by increasing energy
harvesting from dietary ﬁbers. The intestinal microbiota
breaks down indigestible polysaccharides (i.e., ﬁber) to
short-chain fatty acids (SCFAs) providing 80 to 200kcal
per day or about 4–10% of daily energy intake in normal
adults [41]. Metagenomic analysis of ob/ob cecal microbiota
revealed that ob/ob-speciﬁc gut microbiota was enriched
with bacterial genes capable of utilizing and fermenting
dietary ﬁbers [17]. The greater cecal SCFA concentrations
of acetate and butyrate and lower fecal energy contents of
ob/ob than in lean animals suggest additional absorption
of SCFA was absorbed by the intestine of the ob/ob mice
[17]. Murphy et al. independently evaluated whether energy
harvesting is diﬀerent between ob/ob and lean mice and
found a similar result to that obtained by Turnbaugh et al.
with 7-week-old mice but not at 15-weeks-old animals as
older mice showed a similar amount of cecal SCFAs and
fecal energy [28]. The concept of changing energy harvesting
by the gut microbiota has also been tested in humans.
Jumpertz et al. reported that the amount of stool energy
in proportion of ingested calories was positively correlated
with the abundance of phylum Bacteroidetes and negatively
correlated with the abundance of phylum Firmicutes in the
feces [20]. An estimate of 150kcal diﬀerence can be achieved
with a change of 20% relative abundance of Firmicutes
and corresponding decrease of Bacteroidetes in the stool of
lean individuals. Thus, excessive calories taken in the form
of SCFAs from microbiota metabolism of ﬁber may be a
contributing factor in the obese state.
3.3.4. Food Intake and Energy Expenditure. Food intake and
energyexpenditurearetwokeyfactorsthatdetermineenergy
balance in humans and animals. In humans, the role of
gut microbiota in food intake has not been tested, and in
animals the results are inconclusive. As nicely summarized
by Wostmann, earlier work from the 1960s and 70s showed
that food intake is lower in GF than in Conv rats [42].
B¨ ackhed et al. showed that GF C57BL/6J mice consumed
more chow than Conv mice [35]; however, no relationship
was found between chow intake and the presence or absence
of the gut microbiota in C3H mice ([40]a n dp e r s o n a l
communicationwithProfessorMichaelBlaut).OnaWestern
diet, reported food intake in GF and Conv mice was
similar, regardless of their genetic background ([34, 40]a n d
personal communication with Professor Michael Blaut). On
a semisynthetic high-fat diet, we observed that GF C57BL/6J
mice consumed a less amount of food than Conv mice in a
10-week feeding experiment [36], but the same relationship
was not observed in C3H mice [40]. Inconsistent ﬁndings of
foodintakeinGFmicemightbeduetothespeciesofanimals
(rat versus mouse), strain of mouse (C57BL6/J versus C3H),
the quality of the diet (chow, Western, or high-fat diet), and
the sample size in diﬀerent studies.
Similar to food intake, the role of the gut microbiota
on energy expenditure in humans is not known, and only
limited information is available from animal models. Early
work showed that basal metabolic rate, cardiac output, and
body temperature of GF rats were lower than those of their
Conv counterparts, indicating that microbiota may aﬀectJournal of Obesity 5
energy expenditure in animals [43]. Recent observations also
indicated that the oxygen consumption was 25 to 40% less in
GF than in Conv C57BL/6J mice [34]. This conclusion has
been independently conﬁrmed in GF C3H mice [40]. The
comparison of energy expenditure in diﬀerent gnotobiotic
mice colonized with diﬀerent gut microbiota would be
needed to demonstrate the role of gut microbiota in energy
expenditure.
4.MicrobiotainDiabetesand
CardiovascularDiseases
4.1. Clinical Evidence. Few studies have reported the rela-
tionship between the gut microbiota composition and
disease states, such as diabetes and cardiovascular diseases
(CVDs), in humans. Larsen et al. showed that 16S rDNA
sequences representing the class of Bacteroidetes were
slightly higher in the diabetic subjects than in nondiabetic
subjects, although the diﬀerence was not statistically signiﬁ-
cant [44]. In this study a lower proportion of class Clostridia
and higher proportion of class Betaproteobacteria were
associated with diabetes. Another study compared the fecal
microbiota proﬁle of three groups of subjects (lean control,
obese diabetic, and obese nondiabetic) with a quantitative
PCR technique and found diabetes was associated with a
reduction of Faecalibacterium prausnitzii species [24]. A
case-control study with 16 type 2 diabetics and 12 healthy
controls found decreased B. vulgatus and Biﬁdobacterium in
thediabeticgroup[45].Theinteractionbetweentheoraland
gut microbiota and CVD, in particular atherosclerosis, has
recently been discovered [46]. Interestingly, high abundance
of certain bacteria was found in the atherosclerotic plaques
and in the mouth microbiota, but no relationship was found
between the plaque microbiota and the gut microbiota of
aﬀected patients [46].
4.2. Animal Studies. T h er o l eo ft h eg u tm i c r o b i o t ai nt y p e1
and 2 diabetes has been researched in mouse models. Wen
et al. showed that the development of type 1 diabetes in
MyD88-deﬁcient NOD mice, a model of type 1 diabetes,
was dependent on the presence or absence of the gut
microbiota [47]. Indeed, nearly all GF MyD88-deﬁcient
NOD mice developed diabetes, whereas the ex-GF mice with
the same genetic background colonized with a consortium
of 6 bacteria strains had much reduced incidence. This study
demonstrates that bacterial presence is protective against
development of type 1 diabetes.
Obesity and chronic low-grade inﬂammation are com-
mon aspects of both type 2 diabetes and CVD [48]. We and
others postulated that gut microbiota could contribute to the
onset of insulin resistance. In one study, a 2-week treatment
with broad range antibiotics, norﬂoxacin and ampicillin,
signiﬁcantly reduced the number of the cecal microbiota in
ob/ob mice, and the treated ob/ob mice exhibited marked
reductions in fasting blood glucose levels and glucose
intolerance [49]. Increase of liver glycogen and decrease of
liver triglyceride stores were accompanied with improved
glycemic control. This study showed that metabolic health
was improved in ob/ob mice with reduced gut bacteria. To
further examine if glucose tolerance of mice is aﬀected by
the presence or absence of the gut microbiota, we fed both
GF and Conv C57BL/6J mice with a high-fat diet, and our
results showed that GF mice did not develop diet-induced
obesity and glucose intolerance [36]. Since all results based
on comparisons between the GF and Conv mice cannot
be extrapolated to represent normal physiology, evidence
from microbiota transplantation studies will be needed to
conclude if the gut microbiota composition predisposes the
host to diet-induced glucose intolerance.
5.Possible Mechanisms:How the Gut
MicrobiotaAffects Obesity-Related
Metabolic Diseases
There is a reciprocal relationship between the host and its
microbiome. Changes in the number of bacteria, propor-
tion of certain phylotypes, and bacterial activities of the
microbiome are sensed by the host. The main pathways
by which the host and bacteria interact are when bacteria
or the bacterial metabolites enter the host’s circulation
(Figure 2). There are multiple systems in our body to
sense environmental cues, but the aforementioned bacterial
components and metabolites have been implicated to the gut
microbiota sensing with evidence related to the development
of metabolic diseases.
5.1. Bacterial Components. Our innate immune system is
capable of sensing various type s of bacterial components
via pattern recognition receptors (PRRs). In general, there
are two type s of PRRs, toll-like receptors (TLRs) and Nod-
like receptors (NLRs). TLRs are highly conserved transmem-
brane receptors, and each TLR recognizes speciﬁc ligands
and is capable of activating inﬂammatory responses. In
humans, some TLRs (TLR1, 2, 4, 5, 6, and 10) are expressed
in the cell surface, but other TLRs (3, 7, 8 and 9) locate in the
membrane of endolysosomal compartments [50]. Twenty-
two NLRs have been identiﬁed in humans, but only two of
them (NOD1 and NOD2) are well characterized [51]. In
contrast to TLRs that are associated with membranes, NOD1
andNOD2arelocatedincytoplasm[52].PRRsrecognizethe
structures of bacteria (e.g., LPS, lipoproteins, and peptido-
glycan) in order to signal the immune system of a pathogen.
PRRs not only engage in pathogen sensing, but are also
implicated in the development of metabolic diseases such
as insulin resistance and cardiovascular diseases. Therefore
PRRsareperfectcandidatesforsensingthechangesofthegut
microbiota and more importantly mediating the subsequent
inﬂammatory and metabolic responses.
5.1.1. LPS and TLR4 Sensing. Low-grade inﬂammation is a
common comorbidity of type 2 diabetes and CVD. Although
the cause of metabolic inﬂammation is unclear, there is
evidencetosuggestthatLPSoriginatingfromGram-negative
bacteria in the gut induces low-grade inﬂammation and
insulin resistance [48]. The presence of LPS is constantly6 Journal of Obesity
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Figure 2: Gut microbiota can have an eﬀect on the host’s health via bacterial metabolites, that is, SCFA and TMAO, and immune responses
to bacterial components, that is, TLR4 sensing of LPS. In general, bacterial metabolites have varied eﬀects on metabolism and are markers
of risk for disease, whereas bacterial components cause an innate inﬂammatory response resulting in insulin resistance leading to metabolic
syndrome, type 2 diabetes, and CVD.
monitored by the host via the TLR4 [53], which also recog-
nizes compounds of nonmicrobial origin such as saturated
fatty acids [54]. Evidence has suggested that metabolic endo-
toxemia (LPS, 50–100pg/mL) can cause chronic low-grade
inﬂammation and mild disturbances in energy metabolism
implicated in the development of CVD and type 2 diabetes
[55, 56]. A series of animal experiments has helped elucidate
the relationship between gut microbiota, LPS, diet, and
insulin sensitivity. First, when LPS was chronically infused
to mice, it resulted in mild obesity and hepatic insulin
resistance [33]. Mice deﬁcient in TLR4 were protected from
high-fat-diet-induced obesity and insulin resistance [57–59].
Second, the authors showed increased endotoxemia in mice
consuming a high-fat diet [33, 60]. Finally, it was found that
ob/ob mice or high-fat-diet-fed C57BL/6J mice treated with
ampicillin and neomycin had altered gut microbiota com-
position and reduced endotoxemia with improved glucose
tolerance [61]. Furthermore, a reduction of LPS by prebiotic
(oligo-fructosaccharide) treatment signiﬁcantly enhanced
the whole body glucose tolerance and inﬂammatory markers
in the liver and adipose tissue of mice fed a high-fat diet [62,
63]. Together, these data suggest that LPS enters circulation
more readily while being on a high-fat diet, increased plasma
LPS has a detrimental eﬀect on glucose metabolism, and
alteringthemicrobiotacanalleviateendotoxemiaandinsulin
resistance. Therefore, available evidence suggests that LPS
playsacriticalroleinthedevelopmentofobesity-andobesity
associated insulin resistance and low-grade inﬂammation.
Humanstudieshaveprovidedsupportforthishypothesis
as well. In a cross-sectional study of 50 human subjects,
fasting LPS levels in type 2 diabetics were signiﬁcantly
higher than the age, BMI, and sex-matched nondiabetic
controls [64]. Furthermore, treatment of a subgroup of
newly diagnosed type 2 diabetics with insulin-sensitizing
drugs for 10 weeks decreased both endotoxin and insulin
levels, such that the greater the change in endotoxin, the
greater the change in insulin sensitivity [64]. Risk of incident
diabetes was signiﬁcantly associated with higher endotoxin
(LPS) activity, such that those in the highest quartile of
LPS activity had a 52% increased risk of having diabetes as
compared to the lowest quartile [65]. Elevated LPS levels
in type 1 diabetic and kidney vascular disease (IgAGN)
patients were associated with higher serum triglycerides,
earlier onset of diabetes, increased diastolic blood pressure,
and elevated marker of inﬂammation, monocyte chemoat-
tractant protein-1 [66]. In sum, Pussinen et al. conclude that
“endotoxemia is a key player in the pathogenesis of diabetes
and microbes may have a central role [65].”
Metabolic endotoxemia has been linked to the devel-
opment of CVD as well. In a 5-year epidemiological study
of 516 middle-aged men and women, those with plasma
LPS levels over 50pg/mL had a threefold increase in risk
of developing atherosclerosis while the subpopulation of
smokers or ex-smokers with the same level of LPS had a 13-
fold increase [67]. In another study, endotoxin and TNFα
were elevated systemically in those with acute heart failureJournal of Obesity 7
a sc o m p a r e dt os t a b l eh e a r tf a i l u r eo rn o r m a lc o n t r o l s[ 68].
Nevertheless, intervention studies which lower LPS plasma
levels and cause a subsequent decrease in CVD risk have not
been conducted to our knowledge, and such result would
clarify the importance of LPS in the etiology of CVD.
5.1.2. LPS Transport. The transport of LPS into blood can
be through a number of pathways (Figure 3). Compromised
intestinal tight junctions or “a leaky gut” enhances the pos-
sibility of bacteria translocation and uptake of the bacterial
products. The bacterial products induce an inﬂammatory
response, which is central to the pathophysiology of CVD
and diabetes and provides a link between diseases of the gut
and the vasculature. Indeed, individuals with inﬂammatory
bowel disease were at a higher risk of developing coronary
artery disease despite having lower rates of traditional risk
factors (dyslipidemia, hypertension, obesity, diabetes) than
their age-matched controls in a longitudinal cohort study
[69]. In a study mentioned previously, obesity-prone rats
were found to have increased gut permeability and higher
plasma LPS as compared to obesity-resistant mice [32].
To further explore the mechanism by which leaky gut is
related to the microbiome and diet, Cani et al. found
that male C57BL6/J mice fed a high-fat diet had increased
intestinal permeability and decreased expression of genes
encoding for tight junction proteins, but administration of
antibiotics with the high-fat diet eﬀectively blunted these
negative eﬀects [33, 61]. In follow-up experiments, it was
conﬁrmed that the obese mouse controls had the highest
levels of intestinal permeability; prebiotics were found to
improve markers of intestinal permeability via glucagon-like
peptide-2-mediated and cannabinoid-receptor-1-receptor-
(CB1-) mediated pathways [70, 71].
Another pathway by which LPS may enter the blood
stream is its integration into chylomicrons; however, the
mechanism hasnot been thoroughly elucidated. Itis hypoth-
esized that a certain amount of LPS is present within the
enterocyte [72], attached to or within chylomicrons [73].
When chylomicron formation occurs during fat absorption,
LPS is then transported into the lymph circulation with
chylomicrons. It has been shown in humans that increased
chylomicron formation due to a high-fat meal causes greater
LPS transport postprandially as compared to a low-fat meal
or no meal [60, 74]. Levels of sCD14 and IL-6, both markers
of acute inﬂammation, were elevated after a mixed meal
containing lipid in association with higher LPS levels [75].
In both animal and cellular models, chylomicron formation
stimulated by a high-fat challenge signiﬁcantly enhanced the
transport of LPS from the intestinal lumen or enterocyte to
circulation [73, 75]. This high-fat challenge did not aﬀect
the gut tight junctions in mice, and chemically inhibiting
chylomicron formation in the presence of a high-fat stim-
ulus eﬀectively blocked LPS translocation. Together these
data suggest that there is transcellular and chylomicron-
dependent transport of LPS, which is induced by high-
fat intake. While evidence for a role of LPS in chronic
disease is intriguing, issues related to LPS measurement
and LPS contamination make the study of this mechanism
diﬃcult; therefore, developing a fully quantitative LPS assay
with a greater dynamic range should be considered for
future study. Nevertheless, the role of the gut microbiota in
pathogenesis of diabetes and CVD should not be overlooked
and understanding the contribution of inﬂammation from
gut microbiota may provide insight on new therapies to
decrease disease risk.
5.1.3. Flagellum and TLR5; Structural Lipids and TLR2.
TLR5 is highly expressed in epithelial cells of the intestinal
mucosa [76] and is involved in mediating immune response
through recognition of bacterial ﬂagellin [77]. Vijay-Kumar
et al. discovered that TLR5-knockout (T5KO) mice and
wild-type littermates harboured diﬀerent proﬁles of the
gut microbiota. The changes of T5KO gut microbiota were
mainly at the species level, which is in contrast with the
ob/ob mouse model of obesity, where the alternation of the
microbiota was characterized by a phylum-level shift [78].
In T5KO mice, altered gut microbiota proﬁle was associated
with metabolic syndrome characterized with increased vis-
ceral fat deposition, dyslipidemia, hypertension, and insulin
resistance.ThecauseofmetabolicsyndromebytheT5KOgut
microbiota was demonstrated with a transplantation study,
and the results show that GF wild-type mice receiving the
T5KO gut microbiota developed metabolic syndrome [78].
Similarly, TLR2 recognizes a wide array of molecules
including structural lipids, lipoproteins, and lipopeptides
f o u n do nt h es u r f a c eo fb a c t e r i a[ 79]. Ligand-induced
dimerisation of TLR2 with either TLR1 or TLR6 triggers
a cascade of kinase activations and eventually activation of
NFκB[ 80]. Several groups have shown that lacking TLR2
prevents mice from developing to high-fat-diet-induced
obesity, hepatic steatosis, and insulin resistance [81, 82].
The liver, instead of skeletal muscle and white adipose
tissue, is the major tissue with increased insulin sensitivity
in TLR2-deﬁcient mice [82]. However, disrupting TLR2 in
the skeletal muscle and white adipose tissue with TLR2
antisense oligonucleotides also improved the whole-body
insulin sensitivity of mice [83]. Together, data indicate
several TLRs not only can sense the bacterial structures but
also can mediate insulin resistance once activated.
5.1.4. Peptidoglycan and NOD1 and NOD2. Nucleotide oli-
gomerization domain (NOD) 1 and 2 are intracellular
sensors of bacterial peptidoglycan (PGN). NOD 1 pref-
erentially responds to PGN fragment, containing meso-
diaminopimelic acid (meso-DAP) [84, 85], which was found
widely in Gram-negative but also in some Gram-positive
bacteria, whereas NOD2 recognizes monosaccharide with a
dipeptide stem such as muramyl dipeptide (MDP), which
was found in both Gram-positive and Gram-negative bac-
teria [86, 87]. The role of NODs in controlling immune
responses to bacterial ligand is reviewed by Clarke and
Weisser, and these responses include the activation of innate
defense, mediating antimicrobial peptide production, inﬂu-
encing phagocytosis of neutrophils and macrophages [52].
In addition to their role in regulating innate and adapted
immunity, activation of NODs has been implicated in8 Journal of Obesity
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causing insulin resistance. In isolated human preadipocytes,
a treatment with NOD1 ligand DAP led to an activation
of NF-kB and increase of IL-6 secretion [88]. In 3T3-L1
adipocytes, DAP induces insulin resistance with a decrease
in insulin-stimulated Akt phosphorylation (Ser 473 and
Thr 308) and a reduced phosphorylated IRS-1 (Tyr 632)
[89]. Impaired insulin signalling by DAP or a synthetic
NOD1 ligand FK565 translated to a signiﬁcant reduction
of insulin stimulated glucose uptake in 3T3-L1 adipocytes
[89, 90]. In vivo, the FK565 treatment resulted in whole-
body insulin resistance with decreased glucose infusion
rate, reduced glucose disposal rate, and diminished sup-
pression of hepatic glucose production by insulin during
a hyperinsulinemic euglycemic clamp [90]. The FK565-
induced insulin resistance was absent in mice deﬁcient
in functional NOD1, which suggests the functional role
of NOD1 activation in causing whole-body insulin resis-
tance [90]. Similar to NOD1, activation of NOD2 also
has been shown to induce insulin resistance. Tamrakar
et al. reported that addition of NOD2 ligand MDP dose
dependently suppressed basal and insulin-stimulated 2-DG
glucose uptake in the cultured L6-GLUT4myc myotubes
[91]. These data suggest that bacterial PGN can cause
insulin resistance in tissues but each insulin-sensitive tis-
sue responds to a diﬀerent bacterial PGN. The liver and
adipose tissue primarily react to NOD1 ligand whereas
skeletal muscle preferentially reacts against NOD2 ligand.
Together, available data suggest that bacterial PGN frag-
ments can cause insulin resistance and PRRs such as
NOD1 and NOD2 are responsible for triggering a cascade
of events leading to inﬂammatory responses and insulin
resistance.
5.2. Bacterial Metabolites. Bacterial metabolites encompass a
group of molecules found in circulation that are a product
of bacterial metabolism. The following bacterial metabolites:
SCFA, TMAO, and hippurate, have been shown to aﬀect
diabetes or CVD risk.
5.2.1. SCFA Production and Bacterial Composition. Gut
microbes ferment indigestible material in the colon to
produce SCFAs, which is aﬀected by the composition of the
gut microbiota. Martin et al. applied 1HNMR spectroscopic
analysis and examined the metabonomic proﬁles of feces
frommicecolonizedwithdiﬀerentgutmicrobiota[92].Mice
colonized with a human baby microbiota with a supplement
of L. Paracasei diﬀered from conventional and conventional-
ized mice with less fecal butyrate and propionate and more
succinate. However, near identical metabonomic pattern was
observed between the conventional and conventionalized
mice. In another study, conventional rats were treated
with penicillin and streptomycin, and the amounts of fecal
acetate, n-butyrate, and propionate were greatly reduced
by the treatment [93]. These results clearly demonstrated
the changes of fecal SCFA concentrations as a result of gut
microbiota modulation. Turnbaugh et al. have looked at the
role gut microbiota proﬁle plays in the production of SCFA
at two levels: the capacity to produce SCFA and the type
of SCFA produced. By looking at metagenomic diﬀerences
between lean and obese mice, a higher concentration of
butyrate and acetate in the caeca of obese mice was
observed, while propionate was not signiﬁcantly diﬀerent
between the two groups [17]. Although the increase in SCFA
production capacity may be directly linked to the diﬀerence
in microbiota proﬁle between lean and obese Conv mice,Journal of Obesity 9
other confounding factors such as calorie and ﬁber intake
associated with the hyperphagic phenotype of ob/ob mice
could be driving the upward changes in SCFA production
and should be considered in future studies.
5.2.2. SCFA and Lipid Metabolism. As mentioned earlier,
gut-derived SCFAs supply energy to the host. In addition,
SCFAs are suggested to play a role in the regulation of
blood lipids and therefore may have an eﬀect on CVD
risk. The three primary SCFAs produced by microbiota
fermentation are acetate, propionate, and butyrate with the
former two being absorbed into portal circulation and the
latter used as an energy source for colonocytes. Acetate
(or acetyl-CoA) is a substrate for cholesterol synthesis and
is hypothesized to increase in plasma cholesterol, whereas
propionate may decrease cholesterol by inhibiting acetyl-
CoA synthetase activity, the enzyme that converts acetate to
acetyl-CoA. Therefore, propionate is thought to inhibit the
cholesterol-raising eﬀect of acetate; however, the hypothesis
is controversial.
Human studies have provided evidence to support the
acetate: propionate hypothesis. In a cross-sectional study of
normolipidemic men and women, the acetate: propionate
ratio was positively associated with total and LDL cholesterol
in men,butnot women,evenafteradjusting forageandBMI
[94]. Lactulose, a synthetic, nonabsorbable sugar, which is
metabolized by microbiota to produce high levels of acetate,
included in the diet of 6 healthy volunteers for 2 weeks,
resulted in a signiﬁcant increase in total and LDL cholesterol
and apolipoprotein B with a trend towards increased serum
acetate as compared to the control diet [95]. Furthermore, in
a human comparative study using rectal infusions of acetate,
propionate, or both, acetate increased serum cholesterol
whereas propionate did not aﬀect serum cholesterol, and the
combination of the two did not cause an increase in serum
cholesterol [96]. It should be noted that acetate is always
produced to a greater extent than propionate and butyrate,
and in vivo levels of propionate in the portal vein are quite
low [97]; therefore, the optimal acetate:propionate ratio
needed to lower serum cholesterol and how that translates
to ﬁber intake in humans require further study.
Animal and in vitro studies have provided supporting
evidence concerning acetate and propionate’s role in choles-
terol and fatty acid synthesis. The role of propionate in lipid
metabolism and overall health is well reviewed by Hosseini
et al. [97]. However, it is well known that there are many
diﬀerences between the lipid metabolism of rodents and
humans; therefore, more research must be done in models
with similar lipid metabolism, such as hamsters.
5.2.3. SCFA as Signaling Molecules. In addition to their other
physiological roles, SCFAs are signalling molecules which
mayhelp explain some mechanisms by whichgutmicrobiota
aﬀects obesity and chronic diseases. Recently it has been
discovered that SCFAs act as a ligand for G-protein-coupled
receptors GPR41 (FFA3) and GPR43 (FFA2) [98–100]. FFA2
exhibits binding potency to SCFAs in the order of carbon
chain length (C2 = C3 > C4 > C5 = C1), whereas FFA3
prefers to bind SCFAs with longer chain length (C3 = C4 =
C5 > C2 = C1) [98–100]. FFA2 mRNA can be detected
in various tissues, and the highest expression is found in
immune cells such as neutrophils, monocytes, peripheral
blood mononuclear cells, B cells, and polymorphonuclear
cells [98–100]. Expression of FFA2 mRNA was also detected
in the skeletal muscle [100], adipose tissue [101], distal
ileum, and colon [102]. FFA3 is more widely distributed
than FFA2. A high level of FFA3 expression can be found
in the adipose tissue, pancreas, spleen, lymph nodes, bone
marrow,bloodmononuclearcells,and3T3-L1and3T3-F442
preadipocytes [98, 99].
Biological functions of FFA2 and FFA3 in modulating
lipid metabolism have been reported. Infusion of acetate
reduced circulating free fatty acids in C57BL/6J and ob/ob
mice, but the antilipolytic eﬀect was abolished in FFA2-
knockout mice [103], suggesting that FFA2 is partially
responsible for the results of acetate infusion. Therefore,
activation of FFA2 by short-chain fatty acids might be one
of regulatory mechanisms controlling the basal lipolysis and
circulating fatty acid concentrations.
SCFA signaling also aﬀects pathways related to food
intake. Leptin is an adipokine produced by the adipose
tissue, and one of its functions is to negatively control the
food intake. Recently, Xiong et al. demonstrated that SCFAs
such as propionate and butyrate increased the expression of
the leptin gene [104]. Conversely, knockdown of FFA3 by
siRNA almost completely inhibited the ability of propionate
t oi n d u c el e p t i ng e n ee x p r e s s i o n[ 104]. FFA2 is expressed
in peptide-YY-(PYY-) containing enteroendocrine cells, pre-
sumably L cells [102]. Since L cells are also responsible for
the production and secretion of glucagon-like peptide (GLP-
1), it is plausible that SCFAs may aﬀect insulin secretion
via multiple pathways and mechanisms. In support of
this hypothesis, mice deﬁcient in FFA2 showed reduced
insulin secretion in an oral glucose tolerance test (OGTT),
which further suggests the involvement of FFA2 in glucose-
stimulated insulin secretion [105].
5.2.4. Trimethylamine-N-Oxide (TMAO). Microbial metab-
olism of phosphatidylcholine may play a role in atheropro-
gression. Phosphatidylcholine is a phospholipid integral to
cell membranes and present in higher-fat foods. Gut micro-
biota releases choline from dietary phosphatidylcholine
whereitisthenmetabolizedtotrimethylamine(TMA).TMA
is transported to the liver via the portal vein where it is
oxidized by ﬂavin monooxygenase-3 to trimethylamine-N-
oxide (TMAO). Wang et al. showed that increasing levels
of plasma TMAO, choline, and betaine had dose-dependent
relationships with the presence of CVD in a cohort of
1,876 men and women, after controlling for established risk
factors and medication use [106]. The same group further
demonstrated that atherosclerosis-prone mice fed either
high-cholineorTMAOdietshadhigherTMAOplasmalevels
and enhanced total aortic root atherosclerotic plaque area
without any diﬀerences in plasma lipids or glucose. While
the microbiota is necessary for methylamine production
(GF mice do not excrete TMA), dietary interventions can10 Journal of Obesity
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modulate the metabolic outcomes. Conv mice fed high-fat
diets had higher conversion of choline to methylamines as
compared to those on low-fat diets [107]. Elevated plasma
TMAO also is a signature biomarker of a high-meat diet as
comparedtolow-meatandvegetariandietsinhumans[108].
TMAO not only is a new biomarker for developing CVD but
also a novel biomarker for food choice behavior.
5.2.5. Hippurate. Production of hippurate requires both
microbial and mammalian metabolism. Low-molecular-
weight aromatic compounds and polyphenols from the diet
are metabolized by intestinal bacteria, resulting in a produc-
tionofbenzoicacid.Then,inthelivermitochondria,benzoic
acid is conjugated with glycine to form hippurate, which
subsequently is excreted into urine [109]. Therefore, urinary
hippurate has been recognized as a marker of gut microbiota
activity. Interestingly, urinary hippurate, acetate, and propi-
onate were found lower in obese and insulin resistant Zucker
(fa/fa) rats than in wild-type (-/-) or heterozygous mutation
(fa/-) rats [110]. In humans, the amount of urinary hippu-
rate discriminates the morbidly obese and insulin-resistant
patients from age-matched control subjects [111]. In partic-
ular, obese urinary metabolic proﬁle was characterized with
alower level of hippurate than that oflean controls.Recently,
hippurate has been suggested as a biomarker discriminating
people with elevated blood pressure from normotensive
subjects. In the INTERMAP study, which collected 24-hour
urine samples from 4630 participants in China, Japan, UK,
and USA, an inverse association was found between the
urinary hippurate and blood pressure [112]. Together, data
suggest that metabolites of the gut microbiota origin hold
a great promise as a diagnostic marker for people at the
risk of obesity or cardiovascular diseases. However, since the
intakes of dietary polyphenols found in fruits and vegetables
can potentially aﬀect the amount of urinary hippurate, both
dietary habits and gut microbial metabolic activities should
be considered when examining the association between
urinary hippurate and metabolic diseases.
6. Conclusion
Obesity and its associated diseases such as type 2 diabetes
and CVD are increasing at an alarming rate. During the
past years, the discovery of the roles of the gut microbiota
in energy homeostasis raised the question of whether com-
mensal intestinal bacteria are friends or foes in maintaining
a healthy weight. As summarized in this paper, published
results so far do not oﬀer a clear answer to this question.
Factors speciﬁc to individuals, such as dynamic changes of
microbiotaandbehavioralandgeneticpredispositions,likely
work in a concert to determine the response of an individual
toincreasedadiposestores.Thus,gutmetagenomeshouldbe
considered as a risk factor joining the classic factors such as
hostgeneticsandenvironmentalfactsforthedevelopmentof
metabolic diseases (Figure 4).
Low-grade inﬂammation, increased oxidative stress, dys-
lipidemia, hypertension, and insulin resistance have all been
linked with obesity. Thus far, many questions regarding
the microbiota and obesity have been researched, such as
do microbiota in the gut inﬂuence body weight, how do
diﬀerent gut microbiota proﬁles aﬀect mucosal immune
sensing, how is the production of bacterial metabolites
regulated in the gut, and what are the impacts that bacterial
metabolites have onthehumanbody? However,most studies
emphasize on the description of the gut microbiota in
diﬀerent populations and associations between bacterial
phylotype s and certain metabolic outcomes. Therefore, it
is paramount that the causality of metabolic diseases by
disturbed gut microbiota be clearly demonstrated. High-
priority questions that remain to be addressed are whether
the gut microbiota should be considered as a pharmaceutical
or nutritional treatment target for diabetes and CVD andJournal of Obesity 11
what would be the ideal gut microbiota proﬁle to prevent or
to delay the onset of metabolic diseases.
For future study in this ﬁeld, it is reasonable to rely
on a classical approach to identify pathogens in the gut
that could help explain metabolic diseases. However, taking
a more global approach and regarding the gut microbiota
as an ecosystem would be more appropriate. Speciﬁcally,
research addressing the functionality rather than composi-
tion of the gut microbiota should be encouraged. Numerous
human metagenome projects, such as MetaHIT (EU and
China), MicrOBES (INRA, France), Meta-GUT (China), the
Canadian Microbiome Initiative (Canada), and the NIH
Human Gut Metagenome Initiative (USA), are currently on-
going. Metaproteomics of human gut microbiota has been
published [113], and nontargeted metabonomic proﬁling
has recently been used to study the interactions between
the gut microbiota and its host [92, 110]. Omics platforms
are undoubtedly powerful tools to study the role of the gut
microbiota in health and diseases. Hopefully, in the near
future it will be possible to consolidate data from multiple
omic platforms and identify whether certain proﬁles of gut
microbiota or particular microbiota functionalities are a
friend or foe of metabolic health. This would allow the
design of proper diagnostic tools and therapeutic strategies
to treat the consequences caused by dysbiosis between the
gut microbiota and its host. In our opinion, gut microbiota
may play an intriguing role in the development of obesity
andobesity-relateddiseases,and,althoughmicrobiotaseems
strongly associated with obesity, a clear causal relationship
remains to be established.
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